胎儿开放性神经管缺陷宫内修复术前行染色体微阵列分析的意义
回顾性队列研究纳入2011年9月至2021年7月单中心146例符合MOMS标准且核型正常的开放性神经管缺陷胎儿,其中77例(52.7%)行染色体微阵列分析(CMA),65例(84%)结果正常、12例(16%)检出可报告拷贝数变异(CNV,其中2例为致病性)。两组手术特征、妊娠结局及运动功能无显著差异;作者认为产前检出开放性神经管缺陷时应提供CMA检测,可报告CNV不应先验影响宫内修复资格,显著CMA结果需多学科个案讨论。
要点
- CMA可报告CNV组与正常CMA组的手术特征、妊娠结局及新生儿运动功能无显著差异。
- 产前检出开放性神经管缺陷时,作者建议应提供CMA检测以辅助预后与再发风险咨询。
- 可报告CNV不应先验影响宫内修复资格,显著CMA结果需多学科个案讨论评估。
核心结论
- 产前检出开放性神经管缺陷时应提供CMA检测以辅助预后与再发风险咨询;可报告CNV的存在不应先验影响宫内修复资格,因总体妊娠结局与正常CMA病例相似,但显著CMA结果需多学科个案讨论评估资格。
研究设计与样本
- 单中心回顾性队列研究,2011年9月至2021年7月共146例符合MOMS标准且核型正常的开放性神经管缺陷胎儿接受宫内修复,其中77例(52.7%)行CMA检测并按有无可报告CNV分为可报告CNV组(12例)与正常CMA组(65例)。
诊断标准与关键数值
- CMA结果:77例中65例(84%)正常,12例(16%)可报告CNV,其中2例为致病性;1例为749-kb 22q11.21中央区缺失,累及染色体22低拷贝重复区B-D;1例为1q21.1q21.2间质缺失1.3-Mb。
临床应用与阅片要点
- 作者认为产前检出开放性神经管缺陷时应提供CMA检测以辅助预后与再发风险咨询,可报告CNV不应先验影响宫内修复资格,显著CMA结果需多学科个案讨论评估资格。
局限性
- 本文为单中心系列,结论需更大规模多中心长期研究方可推广。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: In-utero repair of open neural tube defects (ONTD) is an accepted treatment option with demonstrated superior outcome for eligible patients. While current guidelines recommend genetic testing by chromosomal microarray analysis (CMA) when a major congenital anomaly is detected prenatally, the requirement for an in-utero repair, based on the Management of Myelomeningocele Study (MOMS) criteria, is a normal karyotype. In this study, we aimed to evaluate if CMA should be recommended as a prerequisite for in-utero ONTD repair.
METHODS: This was a retrospective cohort study of pregnancies complicated by ONTD that underwent laparotomy-assisted fetoscopic repair or open-hysterotomy fetal surgery at a single tertiary center between September 2011 and July 2021. All patients met the MOMS eligibility criteria and had a normal karyotype. In a subset of the pregnancies (n = 77), CMA testing was also conducted. We reviewed the CMA results and divided the cohort into two groups according to whether clinically reportable copy-number variants (CNV) were detected (reportable-CNV group) or not (normal-CMA group). Surgical characteristics, complications, and maternal and early neonatal outcomes were compared between the two groups. The primary outcomes were fetal or neonatal death, hydrocephalus, motor function at 12 months of age and walking status at 30 months of age. Standard parametric and non-parametric statistical tests were employed as appropriate.
RESULTS: During the study period, 146 fetuses with ONTD were eligible for and underwent in-utero repair. CMA results were available for 77 (52.7%) patients. Of those, 65 (84%) had a normal CMA and 12 (16%) had a reportable CNV, two of which were classified as pathogenic. The first case with a pathogenic CNV was diagnosed with a 749-kb central 22q11.21 deletion spanning low-copy-repeat regions B-D of chromosome 22; the second case was diagnosed with a 1.3-Mb interstitial deletion at 1q21.1q21.2. Maternal demographics, clinical characteristics, operative data and postoperative complications were similar between those with normal CMA results and those with reportable CNVs. There were no significant differences in gestational age at delivery or any obstetric and early neonatal outcome between the study groups. Motor function at birth and at 12 months of age, and walking status at 30 months of age, were similar between the two groups.
CONCLUSIONS: Standard diagnostic testing with CMA should be offered when an ONTD is detected prenatally, as this approach has implications for counseling regarding prognosis and recurrence risk. Our results indicate that the presence of a clinically reportable CNV should not a priori affect eligibility for in-utero repair, as overall pregnancy outcome is similar in these cases to that of cases with normal CMA. Nevertheless, significant CMA results will require a case-by-case multidisciplinary discussion to evaluate eligibility. To generalize the conclusion of this single-center series, a larger, multicenter long-term study should be considered. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Zemet R, Krispin E, Johnson RM, et al. Implication of chromosomal microarray analysis prior to in-utero repair of fetal open neural tube defect. Ultrasound Obstet Gynecol. 2023. PMID: 36610024. doi:10.1002/uog.26152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。